Information Provided By: 
Fly News Breaks for December 5, 2017
SNSS
Dec 5, 2017 | 07:13 EDT
Cantor Fitzgerald analyst Mara Goldstein believes shares of Sunesis Pharmaceuticals could face pressure on the resignation of President and CEO Dan Swisher. The loss, however, is not an indictment of the clinical potential of SNS-062, Goldstein tells investors in a research note. However, the analyst believes the resignation makes it harder for investors to maintain focus on the company without a CEO at the helm, particularly as interim data are not expected until mid-2018. She keeps a Neutral rating on Sunesis with a $3 price target.
News For SNSS From the Last 2 Days
There are no results for your query SNSS
